(425) Biocompatibility assessment of Dexamethasone-Loaded Hydrogel ocular Implants
Introduction: Ocular implants with controlled drug release offer promising solutions to the limitations of conventional ophthalmic formulations, such as low drug bioavailability due to biological barriers, the need for frequent administrations, and poor patient adherence to treatment. These challenges are particularly pronounced during the treatment and prevention of inflammation following eye surgery. Biofabrication and hydrogel cross-linking techniques enable the development of implants from polymers like sodium alginate (ALGS), allowing for customizable properties to meet specific therapeutic needs.
Learning Objectives:
Evaluate the impact of the implants as a solution to the problems of conventional treatments.
Develop ALGS implants for the controlled release of dexamethasone in the anterior chamber of the eye
To estimate the implications of this development for optimizing patient adherence to treatment.
